AAA July 2011 – Page 5

Novo reinvests in Vantia

Denmark-based medical foundation Novo has used its quasi-corporate venturing unit to co-lead the £4m ($6.5m) series B round for Vantia Therapeutics, a UK-based drugs company. Venture capital (VC) firm SV Life Sciences also co-led the B round, which included VC peer MVM Life Science Partners and all existing investors in Vantia. MVM, SV and Novo… Continue reading Novo reinvests in Vantia